„It was a great honor for me to have my work so highly appreciated by Miltenyi Biotec. Attending the ASH 2018 in San Diego was an amazing experience, which allowed me to interact with top scientists from all over the world, to discuss my work and to initiate new partnerships.”
Mgr. Michal ŠMÍDA | Winner of the IOIA 2018 – American Society of Hematology (ASH) Annual Meeting
Central European Institute of Technology (CEITEC) Masaryk University in Brno, Czech Republic
Michal Smida, Ph.D., is a junior research group leader at the CEITEC. His research focuses on personalized medicine for B cell malignancies, in particular developing alternative strategies to combine with immunotherapy regimens and predicting novel therapy targets based on synthetic lethality with patient mutations. His team is mainly using CRISPR/Cas9-based gene editing and cell screening with both whole-genome CRISPR knockout as well as drug libraries.